PTC Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 991

Employees

  • Stock Symbol
  • PTCT

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $56.42
  • (As of Friday Closing)

PTC Therapeutics General Information

Description

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Contact Information

Website
www.ptcbio.com
Formerly Known As
RNA Therapeutics Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 500 Warren Corporate Center Drive
  • Warren, NJ 07059
  • United States
+1 (908)
Primary Industry
Clinics/Outpatient Services
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 500 Warren Corporate Center Drive
  • Warren, NJ 07059
  • United States
+1 (908)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PTC Therapeutics Stock Performance

As of 20-Nov-2026, PTC Therapeutics’s stock price is $56.42. Its current market cap is $4.71B with 83.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$56.42 $58.33 $56.18 - $90.87 $4.71B 83.5M 1.07M -$1.32

PTC Therapeutics Financials Summary

As of 30-Sep-2026, PTC Therapeutics has a trailing 12-month revenue of $1.16B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,873,977 4,821,009 2,868,277 2,489,308
Revenue 1,155,554 1,730,655 806,780 937,822
EBITDA 174,483 887,664 (120,463) (330,340)
Net Income (105,971) 682,644 (363,295) (626,604)
Total Assets 3,207,715 2,898,767 1,705,024 1,895,698
Total Debt 636,034 2,707,064 2,471,072 2,229,123
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PTC Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PTC Therapeutics‘s full profile, request access.

Request a free trial

PTC Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiate
Clinics/Outpatient Services
Warren, NJ
991 As of 2025

San Diego, CA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PTC Therapeutics Competitors (73)

One of PTC Therapeutics’s 73 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avidity Biosciences Formerly VC-backed San Diego, CA
Travere Therapeutics Formerly VC-backed San Diego, CA
Arcturus Therapeutics Holdings Formerly VC-backed San Diego, CA
Pfizer 21 Corporation Ocean, NJ
Rallybio Formerly VC-backed New Haven, CT
You’re viewing 5 of 73 competitors. Get the full list »

PTC Therapeutics Patents

PTC Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260337201-A1 Process for producing crystalline forms of sepiapterin Pending 18-Apr-2025
WO-2026221882-A1 Process for producing crystalline forms of sepiapterin Pending 18-Apr-2025
US-20260078174-A1 Single-chain medi1341 antibody-transferrin fusion protein for enhanced efficacy and indications Pending 16-Sep-2024
US-20260078173-A1 Single-chain zagotenemab antibody-transferrin fusion protein for enhanced efficacy and indications Pending 16-Sep-2024
US-20260070968-A1 Single-chain ustekinumab antibody-transferrin fusion protein for enhanced efficacy and indications Pending 11-Sep-2024 C07K14/79
To view PTC Therapeutics’s complete patent history, request access »

PTC Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PTC Therapeutics Investments & Acquisitions (8)

PTC Therapeutics’s most recent deal was a Corporate Asset Purchase with Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) for . The deal was made on 21-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) 21-Sep-2026 Corporate Asset Purchase Buildings and Property
ONODERA GT Pharma 31-Oct-2022 Later Stage VC Biotechnology
Censa Pharmaceuticals 29-May-2020 Merger/Acquisition Drug Discovery
BioElectron Technology (Inflammatory and Central Nervous System Disorders Focussed Assets) 29-Oct-2019 Corporate Asset Purchase Buildings and Property
BioElectron Technology 25-Oct-2019 Merger/Acquisition Drug Discovery
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

PTC Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

27.28 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view PTC Therapeutics’s complete esg history, request access »

PTC Therapeutics FAQs

  • When was PTC Therapeutics founded?

    PTC Therapeutics was founded in 1998.

  • Where is PTC Therapeutics headquartered?

    PTC Therapeutics is headquartered in Warren, NJ.

  • What is the size of PTC Therapeutics?

    PTC Therapeutics has 991 total employees.

  • What industry is PTC Therapeutics in?

    PTC Therapeutics’s primary industry is Clinics/Outpatient Services.

  • Is PTC Therapeutics a private or public company?

    PTC Therapeutics is a Public company.

  • What is PTC Therapeutics’s stock symbol?

    The ticker symbol for PTC Therapeutics is PTCT.

  • What is the current stock price of PTC Therapeutics?

    As of 20-Nov-2026 the stock price of PTC Therapeutics is $56.42.

  • What is the current market cap of PTC Therapeutics?

    The current market capitalization of PTC Therapeutics is $4.71B.

  • What is PTC Therapeutics’s current revenue?

    The trailing twelve month revenue for PTC Therapeutics is $1.16B.

  • Who are PTC Therapeutics’s competitors?

    Avidity Biosciences, Travere Therapeutics, Arcturus Therapeutics Holdings, Pfizer 21, and Rallybio are some of the 73 competitors of PTC Therapeutics.

  • What is PTC Therapeutics’s annual earnings per share (EPS)?

    PTC Therapeutics’s EPS for 12 months was -$1.32.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process